Dermatology's research gap in skin of color is well-documented: a 2020 analysis of 5 leading dermatology textbooks found only 4.5% of images depicted dark skin tones. This underrepresentation has real clinical consequences — delayed diagnosis (melanoma, basal cell carcinoma presenting differently in dark skin), inappropriate treatment choices (procedures with higher PIH risk), and patient dissatisfaction with recommendations derived from lighter skin research. A growing movement in dermatology toward skin of color specialization is producing more relevant evidence. This guide summarizes key evidence-based considerations for clinical skincare and dermatological management in Fitzpatrick types III–VI. Our skin care catalog includes products specifically formulated and tested for diverse skin tones.
Post-Inflammatory Hyperpigmentation (PIH): The Primary Concern
PIH — the dark spots left after any inflammatory skin condition (acne, eczema, injury, procedure-related irritation) — is disproportionately severe and persistent in darker skin tones, because higher baseline melanocyte activity means inflammatory triggers produce larger melanin responses. For darker skin types, PIH prevention is as important as treating the underlying condition: aggressive treatment of acne prevents PIH; gentle product formulations minimize irritation-driven PIH; sun protection (PIH is markedly worsened by UV stimulation of melanocytes) is non-negotiable. Tinted mineral sunscreens with iron oxides provide visible light protection additionally relevant for PIH in darker skin tones. For treating existing PIH: azelaic acid (15–20%) is particularly well-suited for darker skin types — effective depigmenting action with lower irritation risk and no risk of paradoxical hypopigmentation; tranexamic acid 2–5% provides evidence-based brightening; niacinamide 4–10% reduces melanosome transfer.
Procedure Considerations: Higher Risk Populations
Chemical peels, laser procedures, microneedling, and other aesthetic procedures carry higher risk of PIH and post-inflammatory hypopigmentation (PIHypo — hypopigmented spots in very dark skin) in Fitzpatrick types IV–VI. Evidence-based modifications for darker skin: chemical peels — salicylic acid 20–30% preferred over glycolic acid (lower PIH risk in dark skin); superficial peels only without disrupting the basement membrane; pre-conditioning with hydroquinone or azelaic acid 4–8 weeks before procedure. Laser: Q-switched Nd:YAG 1064nm (less melanin competitive absorption than 532nm or 755nm) preferred for targeting dermal chromophores; longer wavelengths, lower fluences, shorter pulse widths, and adequate skin cooling reduce epidermal damage in darker skin. Microneedling: good PIH safety profile in Fitzpatrick types IV–VI when performed correctly — avoiding aggressive settings and ensuring appropriate post-procedure sunscreen and anti-inflammatory skin care.
